Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Feb;18(1):1-6.
doi: 10.1111/j.0924-2708.2006.00110.x.

Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction

Jacqueline J M H Strik  1 , Adriaan Honig  1 , Edwin Klinkenberg  1 , Jeanette Dijkstra  1 , Jelle Jolles  1
Affiliations

Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction

Jacqueline J M H Strik et al. Acta Neuropsychiatr. 2006 Feb.

Abstract

Background: As depression is a considerable risk factor for an unfavourable course of myocardial infarction (MI), antidepressant treatment of post-MI depression and, inherent to MI status, polypharmacy has become an important issue.

Objective: The present study is the first to evaluate cognitive side effects of fluoxetine, as part of a placebo-controlled double-blind trial, in patients with post-first MI depression.

Methods: Cognitive performance of 54 depressed patients post first-MI, treated with fluoxetine or placebo was compared. Cognitive performance was tested before and after 9 weeks of treatment using the Visual Verbal Learning Test, Concept Shifting Task, Stroop Colour-Word Test and Letter-Digit-Substitution Test.

Results: The median number of cardiovascular drugs taken by MI patients was 4.9. There were no differences between the fluoxetine and the placebo group on cognitive performance.

Conclusion: In sum, there were no negative side effects of fluoxetine compared with placebo on cognition in depressed MI patients, simultaneously treated with cardiac drugs.

PubMed Disclaimer